Conquer Cancer Foundation’s Board of Directors Welcomes New Chair

Conquer Cancer Foundation’s Board of Directors Welcomes New Chair

Dr. Thomas G. Roberts, Jr.
In January 2016, Thomas G. Roberts, Jr., MD, a global investor and oncologist, succeeded W. Charles Penley, MD, FASCO, as chair of the Board of Directors of the Conquer Cancer Foundation of ASCO. Dr. Penley, a member of the Conquer Cancer Foundation Board of Directors since 2005, had served as chair for 3 years. Dr. Roberts, a long-time philanthropic supporter of the Foundation and member of the Board of Directors since 2012, most recently served as the Foundation’s secretary.

Dr. Margaret Tempero
"Dr. Roberts shares Dr. Penley's inspiring commitment to the cancer community," said Nancy R. Daly, MS, MPH, executive director and chief philanthropic officer of the Conquer Cancer Foundation. "He also brings a dedication to investing in the young innovators of tomorrow and is focused on the key role translational research plays in treatment advances. We are confident that, under his leadership, we will continue to advance our mission of creating a world free from the fear of cancer."

Mr. Alexander Casdin
Dr. Roberts serves alongside two other newly elected members: Margaret Tempero, MD, FASCO, a past president of ASCO and a pioneer in cancer treatment and research, and Alexander Casdin, an investor focused on the health care sector and a member of the board of a precision oncology company.

Dr. Roberts is currently a managing member and portfolio manager at Farallon Capital Management, LLC, a global institutional asset management firm. Prior to joining Farallon, Dr. Roberts was an attending oncologist at Massachusetts General Hospital, an instructor of medicine at the Harvard Medical School, and a visiting scientist at Massachusetts Institute of Technology. A lecturer at Stanford and Berkeley's business schools, Dr. Roberts also continues to perform research and publish on issues relating to the process of cancer drug development.

Dr. Tempero is the director of the University of California San Francisco (UCSF) Pancreas Center. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. She is currently chief emeritus of the Division of Medical Oncology at UCSF and was the institution's founding deputy director and director of Research Programs. In addition, she is the editor in chief of the Journal of the National Comprehensive Cancer Network and chair of the National Comprehensive Cancer Network Pancreas Cancer Guidelines Panel. Dr. Tempero served as president of ASCO in 2004 and on the U.S. Food and Drug Administration Oncology Drug Advisory Committee from 2007 to 2011.

Mr. Casdin, founder of Reneo Capital Management LP, is a successful health care investor and executive with nearly 20 years of leadership experience. He is currently a board member and audit committee chair of Ignyta Inc., a board member of DiaVacs, and an advisory board member of MD Revolution. In addition, Mr. Casdin serves on the advisory board of the Social Enterprise Program at Columbia Business School, as well as the external advisory board of the Center for Biomedical Engineering at Brown University's School of Engineering, and Brown University's President's Leadership Council.

The following members of the Board of Directors were reappointed for another term:

  • Sandra M. Swain, MD, FACP, FASCO, 2016 Treasurer
  • Claire A. Huang, 2016 Secretary
  • Lawrence H. Einhorn, MD, FASCO, Member
  • Thomas A. Marsland, MD, FASCO, Member
  • Steven T. Rosen, MD, FASCO, Member
  • Aaron Sasson, Member

This article was adapted with permission from ASCO Connection.